Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy

References

• Jemal A, Siegel R, Ward E, . Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717–720.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Gallagher CJ, Gregory WM, Jones AE, . Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4: 1470–1480.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75–88.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZ, Lister TA. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005;18:1–10.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, . Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, . Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, . Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology v.1.2010, Non Hodgkin's Lymphomas. 2010. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2010;377:42–51.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Rituximab maintenance in follicular lymphoma: PRIMA. Lancet 2011;377:4–6.
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russell L, . Cost-effectiveness in health and medicine. 1st ed. New York: Oxford University Press; 1996.
   Google Scholar
• Russell LB, Gold MR, Siegel JE, . The role of cost-effectiveness analysis in health and medicine. Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1172–1177.
   PubMed Web of Science ®Google Scholar
• Siegel JE, Weinstein MC, Russell LB, . Recommendations for reporting cost-effectiveness analyses. Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1339–1341.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Russell LB, . Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253–1258.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853–2858.
   PubMed Web of Science ®Google Scholar
• Arias E. National Vital Statistics Report. 2010. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf
   Google Scholar
• Centers for Medicare and Medicaid Services. CMS Physician Fee Schedule. 2010. Available from: http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
   Google Scholar
• List of MS-DRGs, relative weighting factors and geometric and arithmetic mean length of stay. 2010. Available from: http://www.cms.gov/AcuteInpatientPPS/10FR/itemdetail.asp
   Google Scholar
• Guadagnolo BA, Punglia RS, Kuntz KM, . Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006;24:4116–4122.
   PubMed Web of Science ®Google Scholar
• Hayslip J, Simpson K. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65 - 70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008;8:166–170.
   PubMedGoogle Scholar
• Wild D, Walker M, Pettengell R, . Utility elicitation in patients with follicular lymphoma. Value Health 2006;9:A294.
   Web of Science ®Google Scholar
• Pettengell R, Donatti C, Hoskin P, . The impact of follicular lymphoma on health-related quality of life. Ann Oncol 2008;19: 570–576.
   PubMed Web of Science ®Google Scholar
• Weinstein M, O'Brien B, Hornberger J, . Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 2003;6:9–17.
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Weinstein M, Torrance GW. Time preference. In: Gold M, Siegel J, Russell L, ., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. pp 214–246.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Kutikova L, Bowman L, Chang S, . Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535–1544.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853–2858.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Burris HA 3rd, . Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261–4267.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, . Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607–1614.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, . CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Schmitz SF, Utiger U, . Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480–4484.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, . Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011;103:1799–1806.
   PubMed Web of Science ®Google Scholar
• International Society of Pharmacoeconomic Outcomes and Research, Society of Medical Decision Making. Joint Modeling Good Research Practices Task Force. Modeling good research practices. 2012. Available from: http://www.ispor.org/TaskForces/GRPModelingTf.asp
   Google Scholar
• Rituxan [package insert]. South San Francisco, CA: Genentech Inc.; 2011.
   Google Scholar